Literature DB >> 30498729

Surgical antimicrobial prophylaxis in intensive care unit (ICU) patients: a preliminary, observational, retrospective study.

Gary Duclos1, Bruno Pastene1, Fanny Depeyre1, Zoé Meresse1, Nadim Cassir2, Ignacio Martin-Loeches3, Sharon Einav4, Laurent Zieleskiewicz1, Marc Leone1.   

Abstract

BACKGROUND: Surgical antimicrobial prophylaxis (SAP) is supported by evidence-based guidelines. Nevertheless, SAP guidelines do not cover all clinical scenarios. To our knowledge, no information is available regarding SAP in the critically ill patients. We designed a retrospective, observational and preliminary study which the objective was to describe our professional practices in intensive care unit (ICU) patients requiring SAP.
METHODS: All patients admitted for more than 48 h in the ICU and requiring surgery were retrospectively included from January 1st to December 31, 2016. We collected data related to infection, colonization and antimicrobial treatments pre- and post-operatively. We assessed the compliance of SAP to guidelines.
RESULTS: Among 41 included patients, 13 (32%) were treated for an ongoing infection and 21 (51%) received at least one antibiotic during the ICU stay. Seven (17%) were colonized. Twenty-one (51%) patients received SAP according to guidelines. Thirteen postoperative infections including 1 surgical site infection were reported. For 10 (24%) patients, the ongoing antimicrobial treatment was continued in the operating room. No surgical site infection and 1 lung infection was reported. In 3 (7%) patients, no SAP was administered and 1 episode of bacteremia was noted. Three (7%) patients had their ongoing treatment changed in the operating room. Two of them developed a lung infection. The other patients were assessed individually due to complex conditions.
CONCLUSIONS: These preliminary data showed a large heterogeneity in the management of SAP in the ICU, suggesting the need for specific guidelines based on clinical trials.

Entities:  

Keywords:  Surgical antimicrobial prophylaxis (SAP); intensive care unit (ICU); microbiology

Year:  2018        PMID: 30498729      PMCID: PMC6230858          DOI: 10.21037/atm.2018.09.56

Source DB:  PubMed          Journal:  Ann Transl Med        ISSN: 2305-5839


  18 in total

1.  Control of Enterobacteriaceae producing extended-spectrum beta-lactamase in intensive care units: rectal screening may not be needed in non-epidemic situations.

Authors:  Michelle Thouverez; Daniel Talon; Xavier Bertrand
Journal:  Infect Control Hosp Epidemiol       Date:  2004-10       Impact factor: 3.254

Review 2.  Antimicrobial prophylaxis in minor and major surgery.

Authors:  M Bassetti; E Righi; A Astilean; S Corcione; A Petrolo; E C Farina; F G De Rosa
Journal:  Minerva Anestesiol       Date:  2014-02-24       Impact factor: 3.051

3.  Beta-Lactam Infusion in Severe Sepsis (BLISS): a prospective, two-centre, open-labelled randomised controlled trial of continuous versus intermittent beta-lactam infusion in critically ill patients with severe sepsis.

Authors:  Mohd H Abdul-Aziz; Helmi Sulaiman; Mohd-Basri Mat-Nor; Vineya Rai; Kang K Wong; Mohd S Hasan; Azrin N Abd Rahman; Janattul A Jamal; Steven C Wallis; Jeffrey Lipman; Christine E Staatz; Jason A Roberts
Journal:  Intensive Care Med       Date:  2016-01-11       Impact factor: 17.440

4.  Antimicrobial prophylaxis is critical for preventing surgical site infection.

Authors:  Gary Duclos; Laurent Zieleskiewicz; Marc Leone
Journal:  J Thorac Dis       Date:  2017-09       Impact factor: 2.895

5.  Surgical Antibiotic Prophylaxis and Risk for Postoperative Antibiotic-Resistant Infections.

Authors:  Margot E Cohen; Hojjat Salmasian; Jianhua Li; Jianfang Liu; Philip Zachariah; Jason D Wright; Daniel E Freedberg
Journal:  J Am Coll Surg       Date:  2017-10-10       Impact factor: 6.113

6.  Guideline for Prevention of Surgical Site Infection, 1999. Centers for Disease Control and Prevention (CDC) Hospital Infection Control Practices Advisory Committee.

Authors:  A J Mangram; T C Horan; M L Pearson; L C Silver; W R Jarvis
Journal:  Am J Infect Control       Date:  1999-04       Impact factor: 2.918

7.  Timing of surgical antimicrobial prophylaxis: a phase 3 randomised controlled trial.

Authors:  Walter P Weber; Edin Mujagic; Marcel Zwahlen; Marcel Bundi; Henry Hoffmann; Savas D Soysal; Marko Kraljević; Tarik Delko; Marco von Strauss; Lukas Iselin; Richard X Sousa Da Silva; Jasmin Zeindler; Rachel Rosenthal; Heidi Misteli; Christoph Kindler; Peter Müller; Ramon Saccilotto; Andrea Kopp Lugli; Mark Kaufmann; Lorenz Gürke; Urs von Holzen; Daniel Oertli; Evelin Bucheli-Laffer; Julia Landin; Andreas F Widmer; Christoph A Fux; Walter R Marti
Journal:  Lancet Infect Dis       Date:  2017-04-03       Impact factor: 25.071

8.  International study of the prevalence and outcomes of infection in intensive care units.

Authors:  Jean-Louis Vincent; Jordi Rello; John Marshall; Eliezer Silva; Antonio Anzueto; Claude D Martin; Rui Moreno; Jeffrey Lipman; Charles Gomersall; Yasser Sakr; Konrad Reinhart
Journal:  JAMA       Date:  2009-12-02       Impact factor: 56.272

9.  Assessment of five screening strategies for optimal detection of carriers of third-generation cephalosporin-resistant Enterobacteriaceae in intensive care units using daily sampling.

Authors:  P Grohs; I Podglajen; E Guerot; F Bellenfant; A Caumont-Prim; G Kac; B Tillecovidin; E Carbonnelle; G Chatellier; G Meyer; J Y Fagon; L Gutmann
Journal:  Clin Microbiol Infect       Date:  2014-07-25       Impact factor: 8.067

Review 10.  Timing of preoperative antibiotic prophylaxis in 54,552 patients and the risk of surgical site infection: A systematic review and meta-analysis.

Authors:  Stijn Willem de Jonge; Sarah L Gans; Jasper J Atema; Joseph S Solomkin; Patchen E Dellinger; Marja A Boermeester
Journal:  Medicine (Baltimore)       Date:  2017-07       Impact factor: 1.889

View more
  1 in total

1.  Antibiotic prophylaxis in the ICU: to be or not to be administered for patients undergoing procedures?

Authors:  Ignacio Martin-Loeches; Marc Leone; Sharon Einav
Journal:  Intensive Care Med       Date:  2019-11-28       Impact factor: 17.440

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.